Plunkett Research Online: Akero Therapeutics Inc

AKERO THERAPEUTICS INC (AKRO:NAS) Company Profile, Corporate Revenues, Growth, Market Size, Analysis, Business Forecasts, Market Share, Metrics, SWOT

Akero Therapeutics, Inc., together with its wholly-owned subsidiary Akero Securities Corporation, is a cardio-metabolic non-alcoholic steatohepatitis (NASH) company developing medicines designed to restore metabolic balance and improve the overall health of patients with NASH. NASH is a severe form.....



Akero Therapeutics Inc
Ticker: AKRO
Exchange: NAS
Parent Company:
Year Established:
Employees:
Fiscal Year Ends in

Phone: 650 487-6488
Fax:
Address: 170 Harbor Way
3rd Floor
South San Francisco, CA 94080 United States

Map
Types Of Business
Industry Ranks

Industry NAICS code:

Pharmaceutical Preparation Manufacturing
Contacts Description

Andrew Cheng CEO/Director/President
William White CFO/Executive VP/Other Corporate Officer
See More
Akero Therapeutics, Inc., together with its wholly-owned subsidiary Akero Securities Corporation, is a cardio-metabolic non-alcoholic steatohepatitis (NASH) company developing medicines designed to restore metabolic balance and improve the overall health of patients with NASH. NASH is a severe form.....See More See More

Auditor: Deloitte & Touche LLP
Legal Advisor:
$USD, In whole numbers,
except marked * or %
2020 2019 2018
Financials
    Revenue
    Cost of Revenue
    Gross Margin %
    R&D Expense
    Operating Income
    Operating Margin %
    SGA Expense
    Net Income
    Earnings Per Share
    Dividends
    Book Value Per Share
    Operating Cash Flow
    Capital Expenditure
    Free Cash Flow
Profitability
    EBITDA
    Return on Assets %
    Return on Equity %
    Net Margin %
    Assets Turnover
    Financial Leverage
Brands, Divisions and Affiliates Top Salaries
Akero Securities Corporation
Efruxifermin
Name Title Salary (US$) Bonus (US$)
Other Thoughts Corporate Culture

Apparent Female Officers or Directors: